Deuterium

LG Display Unveils Third-Generation OLED TV Panel at CES 2023

Retrieved on: 
Thursday, January 5, 2023
LG Display, META, Algorithm, Deuterium, CES, OLED TV, OLED, HDR, High dynamic range, Senior, Television, Television set

SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that it will unveil its third-generation OLED TV panel at CES 2023.

Key Points: 
  • SEOUL, South Korea, Jan. 5, 2023 /PRNewswire/ -- LG Display, the world's leading innovator of display technologies, announced today that it will unveil its third-generation OLED TV panel at CES 2023.
  • LG Display's newly-unveiled META Technology comprises a 'Micro Lens Array' that maximizes light emission from the OLED panel and 'META Booster,' a brightness-enhancing algorithm.
  • The company further strengthens its technological leadership in the large-sized OLED panel industry by presenting its cutting-edge META Technology, the culmination of LG Display's 10 years of OLED innovation.
  • With its innovative META Technology, LG Display redefines TV picture quality once again by achieving 2,100-nit peak brightness, the highest level of any TV display on the market today.

Salarius Pharmaceuticals Presents SP-3164 Data Demonstrating Activity in Preclinical Lymphoma Models at the American Society of Hematology Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Life, Cancer prevention, Sarcoma, Clinical trial, Annual report, Effectiveness, Hematological Cancer Research Investment and Education Act, Cancer Prevention and Research Institute of Texas, Letter, Food, FDA, Poster, Safety, Cancer, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Exposition, Trial of the century, ASH, Lenalidomide, Deuterium, SUSAR, Drug discovery, Ewing's sarcoma, Drug development, Research, Society, NHL, Research institute, Biology, Patient, MD Anderson Cancer Center, Rituximab, Vaccine, Pharmaceutical industry, Salinicola salarius, IND, DLBCL

HOUSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, announces that yesterday Daniela Santiesteban, Ph.D., Salarius’ director of targeted protein degradation development, presented positive SP-3164 preclinical data at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition underway in New Orleans and virtually.

Key Points: 
  • Avadomide is an extensively studied clinical compound that has demonstrated encouraging single-agent and combination-therapy efficacy in non-Hodgkin’s lymphomas (NHL) and other hematologic malignancies.
  • This, along with the data presented at ASH showing compelling SP-3164 activity in lymphoma models, supports SP-3164’s potential in NHL for the clinical trial planned for 2023.
  • Salarius may not actually achieve the plans, carry out the intentions or meet the expectations or objectives disclosed in the forward-looking statements.
  • Salarius disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.

CNL and General Fusion Sign MOU to Advance Commercial Fusion Energy

Retrieved on: 
Thursday, November 10, 2022
Program, Science and technology, GLOBE, General officer, Health, Atomic Energy of Canada Limited, Economics, AECL, Waste management, Research, Organization, Environment, Plant, Economic development, Technology, UK Atomic Energy Authority Constabulary, Nuclear, CNL, Area studies, General Fusion, National Nuclear Laboratory, Climate change, Deuterium, Electricity, Government, Hydrogen, Vision 2030, Heart, CEO, Private sector, CNRI, Tritium, MOU, Lithium, Renewable energy, Science

Fusion energy holds great potential as a clean and reliable form of energy for electricity grids, and the MOU will act as a framework for both companies to partner to advance fusion energy research and commercialization.

Key Points: 
  • Fusion energy holds great potential as a clean and reliable form of energy for electricity grids, and the MOU will act as a framework for both companies to partner to advance fusion energy research and commercialization.
  • Overall, the aim is to develop fusion energy research capabilities within CNL, to support the goal of constructing a potential General Fusion commercial power plant in Canada before 2030.
  • CNL is thrilled to build on our commercial relationship with General Fusion, a pioneering company that is advancing a new form of clean energy technology, commented Joe McBrearty, CNLs President and CEO.
  • General Fusion is a Canadian company based in Vancouver and we are excited to advance this framework to collaborate with CNL, a leader in clean energy technologies, said Greg Twinney, CEO, General Fusion.

CNL and General Fusion Sign MOU to Advance Commercial Fusion Energy

Retrieved on: 
Thursday, November 10, 2022
Program, Science and technology, GLOBE, General officer, Economics, Research, Organization, Plant, Economic development, Technology, UK Atomic Energy Authority Constabulary, Nuclear, CNL, Area studies, General Fusion, National Nuclear Laboratory, Climate change, Deuterium, Electricity, Hydrogen, Heart, CEO, CNRI, Tritium, MOU, Lithium, Renewable energy, Science

Fusion energy holds great potential as a clean and reliable form of energy for electricity grids, and the MOU will act as a framework for both companies to partner to advance fusion energy research and commercialization.

Key Points: 
  • Fusion energy holds great potential as a clean and reliable form of energy for electricity grids, and the MOU will act as a framework for both companies to partner to advance fusion energy research and commercialization.
  • Overall, the aim is to develop fusion energy research capabilities within CNL, to support the goal of constructing a potential General Fusion commercial power plant in Canada before 2030.
  • CNL is thrilled to build on our commercial relationship with General Fusion, a pioneering company that is advancing a new form of clean energy technology, commented Joe McBrearty, CNLs President and CEO.
  • General Fusion is a Canadian company based in Vancouver and we are excited to advance this framework to collaborate with CNL, a leader in clean energy technologies, said Greg Twinney, CEO, General Fusion.

Cybin Announces Scientific Presentation at the 5th Annual Neuropsychiatric & Psychedelics Drug Development Summit

Retrieved on: 
Tuesday, November 1, 2022
Biotechnology, Mental Health, Alternative Medicine, Health, Pharmaceutical, Goal, Growth, Inc., DMT, Deuterium, Psychedelic drug, News, Research, Time, NYSE, Patent, U.S. Securities and Exchange Commission, COVID-19, Disease, Mental health, EDGAR, NEO, View, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Health Canada, Company, Therapy, Psilocybin, Patient, Drug development, United Kingdom, Food, Engineering, IV, Summit, Neuropsychiatry, NYSE American, Risk, Pharmaceutical industry, Neuropharmacology

Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced an upcoming presentation at the Neuropsychiatric & Psychedelics Drug Development Summit taking place October 31 to November 2, 2022, in Boston, MA.

Key Points: 
  • Cybin Inc. ( NEO:CYBN ) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics, today announced an upcoming presentation at the Neuropsychiatric & Psychedelics Drug Development Summit taking place October 31 to November 2, 2022, in Boston, MA.
  • I am delighted to be participating in the 5th Neuropsychiatric and Psychedelics Drug Development Summit to showcase the preclinical data that the team at Cybin have generated based on our CYB004 program.
  • I look forward to engaging with thought-leaders in the field of psychedelic drug development who share our goals of developing improved treatment options for people suffering from mental health conditions.
  • The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

Poxel to Present DESTINY-1 Phase 2 Results for PXL065 in NASH at AASLD The Liver Meeting® 2022

Retrieved on: 
Wednesday, October 12, 2022
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, ACSL4, Non-alcoholic fatty liver disease, Pioglitazone, Euronext Paris, ADPKD, Liver cancer, American Association, Association, Adrenoleukodystrophy, Biomarker, Adenosine, American Association for the Study of Liver Diseases, QD, Lists of diseases, Fibrosis, Inflammation, Company, Obesity, Bone, Degenerative disease, Cirrhosis, European Association for the Study of the Liver, ALD, Liver failure, FDA, Time, Risk, Deuterium, EASL, Edema, Weight gain, AASLD, Type 2 diabetes, Disease, Triglyceride, Cholesterol, Histology, Partnership, Human, National Disaster Management Authority (India), AMPK, Safety, MPC, Forward-looking statement, Fatty liver disease, Institute of Liver and Biliary Sciences, Pharmaceutical industry, Medical imaging, Copper, Euronext, Liver, Imeglimin, Patient

The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.

Key Points: 
  • The study also assessed the effects of PXL065 on liver histology and other metabolic and non-metabolic biomarkers.
  • Analysis of histologic changes was based on paired liver biopsies in PXL065 vs. placebo-treated NASH patients before and after the 36-week treatment period.
  • Across all PXL065 treatment arms (pooled data), 39% of patients had fibrosis improvement by 1 stage without worsening NASH (%) vs. 17% with placebo.
  • For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1).

Cambridge Isotope Laboratories, Inc. (CIL) Partners With ISOtopic Solutions to Release the New Stable Isotope-Labeled and Unlabeled Crude Lipid Yeast Extracts

Retrieved on: 
Monday, September 26, 2022
Isotope, Cat, Organic acid, University, Canada, Intention, Mass spectrometry, CIL, Otsuka Pharmaceutical, CEO, OLED, Solution, Lipidomics, Biomass, Research, GLOBE, ABX, Lipid, Deuterium, Lithium, Aluminium, Xenia

TEWKSBURY, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cambridge Isotope Laboratories, Inc. (CIL) has partnered with ISOtopic Solutions to release the new stable isotope-labeled and unlabeled Crude Lipid Yeast Extracts.

Key Points: 
  • TEWKSBURY, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cambridge Isotope Laboratories, Inc. (CIL) has partnered with ISOtopic Solutions to release the new stable isotope-labeled and unlabeled Crude Lipid Yeast Extracts.
  • Andrew goes on to say: "A major benefit of the stable isotope-labeled lipid yeast extract is that the fatty acids and lipids are uniformly 13C-labeled at highisotopic enrichment.
  • To learn more about these new Crude Lipid Yeast Extracts, as well as the established Metabolite Yeast Extracts (Cat nos.
  • The ISOtopic Solutions product line consists of stable isotope-labeled biomolecules and labeled biomass for the standardization and validation of mass spectrometric analysis methods.

Insights on the Stable Isotope Labeled Compounds Global Market to 2026 - Stable Isotope Studies Aid in Integration of Non-essential Amino Acids in Pea Aphids - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 25, 2022
Chemicals, Plastics, Science, Research, Manufacturing, Metabolomics, Cancer, Research, Toxicity, Deuterium, Metal toxicity, Incidence, Isotope, Mass spectrometry, CAGR, Therapy, Diabetes, NMR, Growth, Metabolism, Proteomics, Patient, Lithium

The "Stable Isotope Labeled Compounds - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Stable Isotope Labeled Compounds - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.
  • Stable isotope labelling comprises the use of non-radioactive isotopes which can act as tracers employed to model various chemical and biochemical systems.
  • Aside from their use in metabolomics research, stable isotope-labeled compounds are finding use in medical diagnostic research, proteomics, and environmental analysis.
  • Stable isotope labeled compounds is witnessing growing use in metabolism mediated toxicity research.

Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress

Retrieved on: 
Monday, August 22, 2022
Biotechnology, Health, Science, Pharmaceutical, Research, Janus, Severity, Yale School of Medicine, Security (finance), Safety, DCE, Autoimmune disease, Alopecia areata, Hair, NASDAQ, JAK2, Disease, Man, Medication, Deuterium, Journal of the European Academy of Dermatology and Venereology, SALT, Private Securities Litigation Reform Act, Anxiety, LinkedIn, Janus kinase, U.S. Securities and Exchange Commission, Depression, Patient, Breakthrough therapy, FDA, Immune system, Twitter, Adult, CNCE, JAK1, Congress, Scalp, Woman, Clinical trial, Life, Moderate, Pharmaceutical industry, Venereology, Dermatology

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at the 31st European Academy of Dermatology and Venereology (EADV) Congress.

Key Points: 
  • Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at the 31st European Academy of Dermatology and Venereology (EADV) Congress.
  • The FDA has granted CTP-543 Breakthrough Therapy designation for the treatment of adult patients with moderate to severe alopecia areata and Fast Track designation for the treatment of alopecia areata.
  • Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body.
  • Concerts lead product candidate CTP-543 is being developed for the treatment of alopecia areata, a serious autoimmune dermatological condition.

Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement

Retrieved on: 
Monday, August 22, 2022
Health, Health Technology, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, Security (finance), NDA, DCE, RA, Alopecia areata, NASDAQ, Exercise, Medication, Deuterium, New Drug Application, Private Securities Litigation Reform Act, LinkedIn, Investment, U.S. Securities and Exchange Commission, Company, Twitter, CNCE, Clinical trial, BVF, Pharmaceutical industry

The exercise period of the tranche 1 and tranche 2 warrants was tied to the clinical success of the Companys CTP-543 THRIVE-AA1 and THRIVE-AA2 Phase 3 trials for alopecia areata.

Key Points: 
  • The exercise period of the tranche 1 and tranche 2 warrants was tied to the clinical success of the Companys CTP-543 THRIVE-AA1 and THRIVE-AA2 Phase 3 trials for alopecia areata.
  • Concert reported positive topline results from the THRIVE-AA1 and THRIVE-AA2 trials in May 2022 and August 2022, respectively.
  • In June 2022, Concert received $18.9 million from the partial exercise of the tranche 1 warrants issued to BVF and RA Capital.
  • Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing small molecule drugs that it discovered through the application of its DCE Platform (deuterated chemical entity platform).